bicalutamide has been researched along with pyrroles in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, J; Liu, B; Liu, J; Su, L; Zhao, G | 1 |
| Cai, J; Hong, Y; Imperato-McGinley, J; Tan, C; Weng, C; Zhu, YS | 1 |
| Corn, PG; DePetrillo, TA; Heath, E; Kuban, D; Maier, J; Mathew, P; Meyn, R; Song, DY | 1 |
| Beraldi, E; Crafter, C; Davies, BR; Fazli, L; Gleave, ME; Kim, S; Lamoureux, F; Thaper, D; Thomas, C; Zoubeidi, A | 1 |
1 review(s) available for bicalutamide and pyrroles
| Article | Year |
|---|---|
Developments in nonsteroidal antiandrogens targeting the androgen receptor.
Topics: Androgen Receptor Antagonists; Anilides; Antineoplastic Agents; Humans; Hydantoins; Imides; Male; Nitriles; Organometallic Compounds; Oxazolone; Prostatic Neoplasms; Pyridines; Pyrroles; Receptors, Androgen; Tosyl Compounds | 2010 |
1 trial(s) available for bicalutamide and pyrroles
| Article | Year |
|---|---|
Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Drug Interactions; Feasibility Studies; Goserelin; Humans; Indoles; Leuprolide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Radiotherapy, Intensity-Modulated; Seminal Vesicles; Sunitinib; Tosyl Compounds | 2013 |
2 other study(ies) available for bicalutamide and pyrroles
| Article | Year |
|---|---|
Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism.
Topics: Androgen Receptor Antagonists; Anilides; Aorta; Cell Proliferation; Cells, Cultured; Cyclin A; Dihydrotestosterone; DNA; Endothelium, Vascular; Estradiol; Gene Expression; Humans; Indoles; Male; Nitriles; Protein Kinase Inhibitors; Purines; Pyrroles; Receptors, Androgen; Roscovitine; Testosterone; Tosyl Compounds; Vascular Endothelial Growth Factor A | 2011 |
Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Topics: Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Disease Progression; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Xenograft Model Antitumor Assays | 2013 |